QRS Duration Is Associated With Atrial Fibrillation in Patients With Left Ventricular Dysfunction

QRSduration (QRSd) is associated with higher mortality and morbidity in patients with left ventricular (LV) dysfunction. The association between QRSd and atrial fibrillation (AF) has not been studied in this patient population.

[1]  R E Brashear,et al.  Arrhythmias in patients with chronic obstructive pulmonary disease. , 1984, The Medical clinics of North America.

[2]  S. Perrone,et al.  Which Patients with Congestive Heart Failure May Benefit from Biventricular Pacing? , 2003, Pacing and clinical electrophysiology : PACE.

[3]  W. Grimm,et al.  How Many Patients with Dilated Cardiomyopathy May Potentially Benefit from Cardiac Resynchronization Therapy? , 2003, Pacing and clinical electrophysiology : PACE.

[4]  K. Swedberg,et al.  Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.

[5]  U. Laufs,et al.  Prevention of Atrial Fibrillation With 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors , 2008, Circulation.

[6]  L H Kuller,et al.  Incidence of and risk factors for atrial fibrillation in older adults. , 1997, Circulation.

[7]  M A Waclawiw,et al.  Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. , 1998, Journal of the American College of Cardiology.

[8]  M. Bourassa.  Angiotensin II inhibition and prevention of atrial fibrillation and stroke. , 2005, Journal of the American College of Cardiology.

[9]  P. Zimetbaum,et al.  Arrhythmias in Patients With Chronic Obstructive Pulmonary Disease (COPD): Occurrence Frequency and the Effect of Treatment With the Inhaled Long-Acting Beta2-Agonists Arformoterol and Salmeterol , 2008, Medicine.

[10]  R. Prescott,et al.  Cardiac size, autonomic function, and 5-year follow-up of chronic heart failure patients with severe prolongation of ventricular activation. , 2003, Journal of cardiac failure.

[11]  W. Kannel,et al.  The natural history of congestive heart failure: the Framingham study. , 1971, The New England journal of medicine.

[12]  J. De Sutter,et al.  Relationship between QRS duration, left ventricular volumes and prevalence of nonviability in patients with coronary artery disease and severe left ventricular dysfunction , 2006, European journal of heart failure.

[13]  G. Somes,et al.  On the relationship between heart weights, fibrosis, and QRS duration. , 1975, Journal of electrocardiology.

[14]  S. Solomon,et al.  Association of QRS duration and outcomes after myocardial infarction: the VALIANT trial. , 2006, Heart rhythm.

[15]  A. Camm,et al.  Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. , 1999, The New England journal of medicine.

[16]  C. Yancy,et al.  Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: findings from Acute Decompensated Heart Failure National Registry (ADHERE). , 2007, American heart journal.

[17]  K. Iwakura,et al.  New approach to the estimation of the extent of myocardial fibrosis in patients with dilated cardiomyopathy: use of signal-averaged electrocardiography. , 1993, American heart journal.

[18]  Luigi Tavazzi,et al.  Left bundle-branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients with congestive heart failure: a report from the Italian network on congestive heart failure. , 2002, American heart journal.

[19]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[20]  I. V. Van Gelder,et al.  Gender-related differences in rhythm control treatment in persistent atrial fibrillation: data of the Rate Control Versus Electrical Cardioversion (RACE) study. , 2005, Journal of the American College of Cardiology.

[21]  W. Kannel,et al.  Incidence and Epidemiology of Heart Failure , 2000, Heart Failure Reviews.

[22]  K. Swedberg,et al.  Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction. , 2008, JAMA.

[23]  K. Kimura,et al.  Relation of atrial fibrillation to glomerular filtration rate. , 2008, The American journal of cardiology.

[24]  A. Auricchio,et al.  Potential benefit of biventricular pacing in patients with congestive heart failure and ventricular tachyarrhythmia. , 1999, The American journal of cardiology.

[25]  J. McMurray,et al.  Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. , 2005, Journal of the American College of Cardiology.

[26]  E. Benjamin,et al.  Current perceptions of the epidemiology of atrial fibrillation. , 2009, Cardiology clinics.

[27]  I. V. Van Gelder,et al.  New risk factors for atrial fibrillation: causes of 'not-so-lone atrial fibrillation'. , 2008, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[28]  S Nattel,et al.  Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. , 1999, Circulation.

[29]  J. Langberg,et al.  The relationship between stature and the prevalence of atrial fibrillation in patients with left ventricular dysfunction. , 2006, Journal of the American College of Cardiology.

[30]  J. Langberg,et al.  Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction. , 2006, Heart rhythm.

[31]  David Cunnington,et al.  Prevalence of sleep disordered breathing in paroxysmal and persistent atrial fibrillation patients with normal left ventricular function. , 2008, European heart journal.

[32]  P. McCullough,et al.  Congestive heart failure and QRS duration: establishing prognosis study. , 2002, Chest.

[33]  W. Stevenson,et al.  Atrial fibrillation and heart failure--five more years. , 2004, The New England journal of medicine.

[34]  W. Stevenson,et al.  Atrial fibrillation in heart failure: high mortality risk even if ventricular function is preserved. , 2005, American heart journal.

[35]  S. Barold,et al.  Significance of QRS complex duration in patients with heart failure. , 2005, Journal of the American College of Cardiology.

[36]  G. Dangas,et al.  A prolonged QRS duration on surface electrocardiogram is a specific indicator of left ventricular dysfunction [see comment]. , 1998, Journal of the American College of Cardiology.

[37]  V. Somers,et al.  Atrial fibrillation and obesity--results of a meta-analysis. , 2008, American heart journal.

[38]  Paul J. Wang,et al.  Echocardiographic evidence of left atrial abnormality in young patients with lone paroxysmal atrial fibrillation. , 2004, The American journal of cardiology.

[39]  R. Sandhu,et al.  Prevalence of QRS prolongation in a community hospital cohort of patients with heart failure and its relation to left ventricular systolic dysfunction. , 2004, The American journal of cardiology.

[40]  A. Cohen-Solal,et al.  Heart failure and diabetes mellitus: epidemiology and management of an alarming association. , 2008, Journal of cardiac failure.

[41]  P. Hildebrandt,et al.  Prevalence and prognostic significance of atrial fibrillation in outpatients with heart failure due to left ventricular systolic dysfunction , 2007, European journal of heart failure.

[42]  P C Deedwania,et al.  Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. , 1998, Circulation.

[43]  A. Costard-Jäckle.  [Atrial fibrillation in heart failure]. , 2002, Herz.

[44]  S G Thompson,et al.  Incidence and aetiology of heart failure; a population-based study. , 1999, European heart journal.

[45]  A. Go,et al.  Racial variation in the prevalence of atrial fibrillation among patients with heart failure: the Epidemiology, Practice, Outcomes, and Costs of Heart Failure (EPOCH) study. , 2004, Journal of the American College of Cardiology.

[46]  J. Floras,et al.  Obstructive sleep apnoea and its cardiovascular consequences , 2009, The Lancet.

[47]  S. Anker,et al.  Clinical characteristics and survival of patients with chronic heart failure and prolonged QRS duration. , 2002, International journal of cardiology.

[48]  Silvia G. Priori,et al.  ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text , 2006 .

[49]  S. Perlini,et al.  Prevention of recurrent lone atrial fibrillation by the angiotensin-II converting enzyme inhibitor ramipril in normotensive patients. , 2009, Journal of the American College of Cardiology.